ArticleAdvances in therapy2026

Beyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

Georgios Vournas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.